A new study shows that using a scoring system that weighs the combined effects of common genetic differences known as variants could improve the ability to predict an individual’s risk of developing ALS. This research was supported in part by the Association.
During this free meeting, presenters will share Registry data and its implications as well as discuss strategies to further improve the Registry. Anyone interested in ALS research is welcome to attend.
QurAlis will leverage Unlearn’s machine learning algorithms to create “digital twins” of individuals participating in clinical trials of QRL-201 and QRL-101.
New research suggests targeting autoimmune inflammation associated with ALS using two drugs, one of which is already approved for the treatment of multiple sclerosis, could be a promising treatment approach.
Results of the latest ALS Focus survey showed approximately one in three ALS claims or prior authorizations were denied by insurance providers. Participants also noted they often had to appeal up to three times and wait up to six months for a final resolution, causing worry, stress, financial burdens and caregiver challenges.
CLICK HERE to see the full results of this survey.
Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website.
The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the U.S. can take part, and there is no fee to participate.
The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments.
For more detail about current ALS research, the projects we fund, and the numerous focus areas we support, visit als.org/research.
Stay up to date with the latest ALS care news by signing up for our quarterly e-newsletter, Care Matters.
We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communication@als.org.